New study tracks safety of clotting drug for hemophilia patients in india
NCT ID NCT07446010
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at the safety and effectiveness of Octocog alfa, a lab-made clotting factor, when used to treat sudden bleeding episodes in adults with severe hemophilia A. About 33 people in India who have used factor VIII before will take part. Researchers will track side effects and how well the drug controls bleeds in everyday medical practice.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEMOPHILIA A are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
All India Institute Of Medical Sciences
New Delhi, India
-
Christian Medical College & Hospital
Ludhiana, India
-
Department of Medicine Assam Medical College & Hospital
Dibrugarh, India
-
Government of Medical College Kozhikode
Kozhikode, India
-
Sahyadri Super Speciality Hospital
Pune, India
-
Sanjay Gandhi Post Graduate Institute & Medical Sciences
Lucknow, India
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A Once-a-Week shot could transform hemophilia Care—Even for those with inhibitors
- Can a new clotting factor offer better bleed protection for severe hemophilia?
- Do newer hemophilia drugs protect joints better? study aims to find out
- New clotting factor aims to cut bleeding episodes in severe hemophilia a
- Newborn screening study aims to catch rare diseases at birth
- New clotting factor aims to stop bleeding in severe hemophilia a